|Bid||13.21 x 1800|
|Ask||13.22 x 1800|
|Day's range||12.85 - 13.80|
|52-week range||9.13 - 14.88|
|Beta (5Y monthly)||N/A|
|PE ratio (TTM)||N/A|
|Forward dividend & yield||N/A (N/A)|
|1y target est||N/A|
NEW YORK, October 08, 2021--Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, is investigating potential claims against Ginkgo Bioworks Holdings, Inc. ("Ginkgo" or the "Company") (NYSE: DNA) on behalf of Ginkgo stockholders. Our investigation concerns whether Ginkgo has violated the federal securities laws and/or engaged in other unlawful business practices.
RADNOR, Pa., October 07, 2021--Kessler Topaz Meltzer & Check, LLP is Investigating Securities Fraud Claims on Behalf of Ginkgo Bioworks Holdings, Inc. (NYSE: DNA) Investors
LOS ANGELES, October 07, 2021--ONGOING INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Ginkgo Bioworks Holdings, Inc.